Literature DB >> 21531951

Strengths and limitations of the six-minute-walk test: a model biomarker study in idiopathic pulmonary fibrosis.

Gustavo A Heresi, Raed A Dweik.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21531951     DOI： 10.1164/rccm.201012-2079ED

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN： 1073-449X            Impact factor:   21.405


× No keyword cloud information.
  17 in total

1.  Abnormal Glucose Metabolism and High-Energy Expenditure in Idiopathic Pulmonary Arterial Hypertension.

Authors:  Gustavo A Heresi; Steven K Malin; Jarrod W Barnes; Liping Tian; John P Kirwan; Raed A Dweik
Journal:  Ann Am Thorac Soc       Date:  2017-02

2.  Interstitial lung abnormalities and reduced exercise capacity.

Authors:  Tracy J Doyle; George R Washko; Isis E Fernandez; Mizuki Nishino; Yuka Okajima; Tsuneo Yamashiro; Miguel J Divo; Bartolome R Celli; Frank C Sciurba; Edwin K Silverman; Hiroto Hatabu; Ivan O Rosas; Gary M Hunninghake
Journal:  Am J Respir Crit Care Med       Date:  2012-01-20       Impact factor: 21.405

3.  Value of impedance cardiography during 6-minute walk test in pulmonary hypertension.

Authors:  Adriano R Tonelli; Laith Alkukhun; Vineesha Arelli; José Ramos; Jennie Newman; Kevin McCarthy; Bohdan Pichurko; Omar A Minai; Raed A Dweik
Journal:  Clin Transl Sci       Date:  2013-09-06       Impact factor: 4.689

Review 4.  End points in heart failure-are we doing it right?

Authors:  Luxitaa Goenka; Melvin George; Sandhiya Selvarajan
Journal:  Eur J Clin Pharmacol       Date:  2017-03-09       Impact factor: 2.953

5.  Cardiopulmonary exercise testing in lung transplantation: a review.

Authors:  Katherine A Dudley; Souheil El-Chemaly
Journal:  Pulm Med       Date:  2012-05-14

Review 6.  The clinical relevance of outcomes used in late-onset Pompe disease: can we do better?

Authors:  Robin Lachmann; Benedikt Schoser
Journal:  Orphanet J Rare Dis       Date:  2013-10-12       Impact factor: 4.123

Review 7.  Understanding and optimizing health-related quality of life and physical functional capacity in idiopathic pulmonary fibrosis.

Authors:  Amy L Olson; Kevin K Brown; Jeffrey J Swigris
Journal:  Patient Relat Outcome Meas       Date:  2016-05-17

8.  Importance of serial changes in biomarkers in idiopathic pulmonary fibrosis.

Authors:  Akihiko Sokai; Kiminobu Tanizawa; Tomohiro Handa; Kumiko Kanatani; Takeshi Kubo; Kohei Ikezoe; Yoshinari Nakatsuka; Shinsaku Tokuda; Toru Oga; Toyohiro Hirai; Sonoko Nagai; Kazuo Chin; Michiaki Mishima
Journal:  ERJ Open Res       Date:  2017-08-30

9.  A study on nonlinear estimation of submaximal effort tolerance based on the generalized MET concept and the 6MWT in pulmonary rehabilitation.

Authors:  Jan Szczegielniak; Krzysztof J Latawiec; Jacek Łuniewski; Rafał Stanisławski; Katarzyna Bogacz; Marcin Krajczy; Marek Rydel
Journal:  PLoS One       Date:  2018-02-09       Impact factor: 3.240

Review 10.  Mesenchymal Stem Cells for the Treatment of Idiopathic Pulmonary Fibrosis.

Authors:  Argyrios Tzouvelekis; Rebecca Toonkel; Theodoros Karampitsakos; Kantha Medapalli; Ioanna Ninou; Vasilis Aidinis; Demosthenes Bouros; Marilyn K Glassberg
Journal:  Front Med (Lausanne)       Date:  2018-05-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.